Skip to main content
Journal ArticleOPEN ACCESS

Instanyl: intranasal fentanyl for treating breakthrough pain

  • Chaplin S
  • Zeppetella G
Prescriber (2010) 21(6) 40-42
DOI: 10.1002/psb.602
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Instanyl is an intranasal formulation of fentanyl licensed for breakthrough pain management in chronic cancer pain. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects and Dr Giovambattista Zeppetella discusses its place in the management of breakthrough pain. Copyright © 2010 Wiley Interface Ltd

Cite

CITATION STYLE

APA

Chaplin, S., & Zeppetella, G. (2010). Instanyl: intranasal fentanyl for treating breakthrough pain. Prescriber, 21(6), 40–42. https://doi.org/10.1002/psb.602

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free